# Type 2 Diabetes Patients With Renal Impairment

> **NCT04221399** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 35 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** DWP16001
- **DRUG:** DWP16001

## Key facts

- **NCT ID:** NCT04221399
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2020-08
- **Final completion:** 2020-10
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221399, "Type 2 Diabetes Patients With Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04221399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*